Patents by Inventor William E. Meek

William E. Meek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods comprising cytostatic protein kinase
    Patent number: 6599726
    Abstract: The present invention presents a unique class of physiological suppressors of cell division and cleavage. In particular, the present invention presents p21-activated protein kinase PAK I, also known as protease activated protein kinase I (with the same abbreviation “PAK I”) which has been purified to apparent homogeneity. PAK I is inactive, e.g. as a protein of about 60 kDa (denoted “p60”, as determined by polyacrylamide gel electrophoresis) and is active when autophosphorylated, for example, following limited proteolysis, or binding of Cdc42, e.g., as a protein of about 58 kDa (denoted “p58” as determined by polyacrylamide gel electrophoresis). The present invention also presents a fragment of PAK I, a peptide denoted p37, which contains the catalytic domain of PAK I. The purification, characterization, nucleotide and amino acid sequences of PAK I and p37 are also disclosed. Another aspect of the invention discloses the cytostatic activity of PAK I and its fragments.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: July 29, 2003
    Assignee: The Regents of the University of California
    Inventors: Jolinda A. Traugh, Regina D. Rooney, Rolf Jakobi, Polygena T. Tuazon, Charng-Jui Chen, William E. Meek, Edward J. Carroll, Jr., Curtis A. Monnig
  • COMPOSITIONS AND METHODS COMPRISING CYTOSTATIC PROTEIN KINASE
    Publication number: 20020086390
    Abstract: The present invention presents a unique class of physiological suppressors of cell division and cleavage. In particular, the present invention presents p21-activated protein kinase PAK I, also known as protease activated protein kinase I (with the same abbreviation “PAK I”) which has been purified to apparent homogeneity. PAK I is inactive, e.g. as a protein of about 60 kDa (denoted “p60”, as determined by polyacrylamide gel electrophoresis) and is active when autophosphorylated, for example, following limited proteolysis, or binding of Cdc42, e.g., as a protein of about 58 kDa (denoted “p58” as determined by polyacrylamide gel electrophoresis). The present invention also presents a fragment of PAK I, a peptide denoted p37, which contains the catalytic domain of PAK I.
    Type: Application
    Filed: January 25, 1999
    Publication date: July 4, 2002
    Inventors: JOLINDA A. TRAUGH, REGINA D. ROONEY, ROLF JAKOBI, POLYGENA TUAZON, CHARNG-JUI CHEN, WILLIAM E. MEEK
  • Compositions and methods comprising cytostatic protein kinase
    Patent number: 5863532
    Abstract: The present invention presents a unique class of physiological suppressors of cell division and cleavage. In particular, the present invention presents p21-activated protein kinase PAK I, also known as protease activated protein kinase I (with the same abbreviation "PAK I") which has been purified to apparent homogeneity. PAK I is inactive, e.g. as a protein of about 60 kDa (denoted "p60", as determined by polyacrylamide gel electrophoresis) and is active when autophosphorylated, for example, following limited proteolysis, or binding of Cdc42, e.g., as a protein of about 58 kDa (denoted "p58" as determined by polyacrylamide gel electrophoresis). The present invention also presents a fragment of PAK I, a peptide denoted p37, which contains the catalytic domain of PAK I. The purification, characterization, nucleotide and amino acid sequences of PAK I and p37 are also disclosed. Another aspect of the invention discloses the cytostatic activity of PAK I and its fragments.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: January 26, 1999
    Assignee: The Regents of the University of California
    Inventors: Jolinda A. Traugh, Regina D. Rooney, Rolf Jakobi, Polygena T. Tuazon, Charng-Jui Chen, William E. Meek, Edward J. Carroll, Jr., Curtis A. Monnig